Bays HE - Search Results

1

Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-titration in patients at moderately high or high risk for coronary heart disease.

Bays HE, Conard SE, Leiter LA, Bird SR, Lowe RS, Tershakovec AM. Bays HE, et al. Int J Cardiol. 2011 Dec 1;153(2):141-7. doi: 10.1016/j.ijcard.2010.08.043. Epub 2010 Sep 15. Int J Cardiol. 2011. PMID: 20837371 Clinical Trial.

2

Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group.

Stein EA, Davidson MH, Dobs AS, Schrott H, Dujovne CA, Bays H, Weiss SR, Melino MR, Stepanavage ME, Mitchel YB. Stein EA, et al. Am J Cardiol. 1998 Aug 1;82(3):311-6. doi: 10.1016/s0002-9149(98)00421-4. Am J Cardiol. 1998. PMID: 9708659 Clinical Trial.

3

Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies.

Bays HE, Moore PB, Drehobl MA, Rosenblatt S, Toth PD, Dujovne CA, Knopp RH, Lipka LJ, Lebeaut AP, Yang B, Mellars LE, Cuffie-Jackson C, Veltri EP; Ezetimibe Study Group. Bays HE, et al. Clin Ther. 2001 Aug;23(8):1209-30. doi: 10.1016/s0149-2918(01)80102-8. Clin Ther. 2001. PMID: 11558859 Clinical Trial.

4

Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients.

Bays HE, Stein EA, Shah AK, Maccubbin DL, Mitchel YB, Mercuri M. Bays HE, et al. Am J Cardiol. 2002 Nov 1;90(9):942-6. doi: 10.1016/s0002-9149(02)02658-9. Am J Cardiol. 2002. PMID: 12398959 Clinical Trial.

5

Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.

Gagné C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, Cho M, Musliner TA, Gumbiner B; Ezetimibe Study Group. Gagné C, et al. Among authors: bays he. Am J Cardiol. 2002 Nov 15;90(10):1084-91. doi: 10.1016/s0002-9149(02)02774-1. Am J Cardiol. 2002. PMID: 12423708 Clinical Trial.

6

Ezetimibe.

Bays H. Bays H. Expert Opin Investig Drugs. 2002 Nov;11(11):1587-604. doi: 10.1517/13543784.11.11.1587. Expert Opin Investig Drugs. 2002. PMID: 12437505 Review.

7

Existing and investigational combination drug therapy for high-density lipoprotein cholesterol.

Bays H. Bays H. Am J Cardiol. 2002 Nov 20;90(10B):30K-43K. doi: 10.1016/s0002-9149(02)02971-5. Am J Cardiol. 2002. PMID: 12467938

8

Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia.

Isaacsohn J, Hunninghake D, Schrott H, Dujovne CA, Knopp R, Weiss SR, Bays H, Crouse JR 3rd, Davidson MH, Keilson LM, McKenney J, Korenman SG, Dobs AS, Stein E, Krauss RM, Maccubbin D, Cho M, Plotkin DJ, Mitchel YB. Isaacsohn J, et al. Clin Cardiol. 2003 Jan;26(1):18-24. doi: 10.1002/clc.4960260105. Clin Cardiol. 2003. PMID: 12539808 Free PMC article. Clinical Trial.

9

Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).

Bays HE, Dujovne CA, McGovern ME, White TE, Kashyap ML, Hutcheson AG, Crouse JR; ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation. Bays HE, et al. Am J Cardiol. 2003 Mar 15;91(6):667-72. doi: 10.1016/s0002-9149(03)00007-9. Am J Cardiol. 2003. PMID: 12633795 Clinical Trial.

10

Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol.

Bays HE, McKenney JM, Dujovne CA, Schrott HG, Zema MJ, Nyberg J, MacDougall DE; Gemcabene Study Group. Bays HE, et al. Am J Cardiol. 2003 Sep 1;92(5):538-43. doi: 10.1016/s0002-9149(03)00721-5. Am J Cardiol. 2003. PMID: 12943873 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

294 results

Search Page